Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alexion
Biotech
AstraZeneca's blockbuster contender hits phase 3 gMG goals
A phase 3 study of gefurulimab has hit its primary and all secondary endpoints, teeing up talks with regulators about the potential blockbuster.
Nick Paul Taylor
Jul 24, 2025 6:20am
AstraZeneca amyloidosis drug fails to reduce mortality in ph. 3
Jul 16, 2025 4:28am
Fierce Pharma
Syntimmune shareholders win again over AZ, this time for $181M
Jun 12, 2025 11:40am
AstraZeneca CEO defends 'fantastic' Alexion buy as halts drug
Feb 6, 2025 6:45am
AZ licenses discarded rare disease drug to Monopar Therapeutics
Oct 24, 2024 2:54pm
AstraZeneca inks $800M buyout to snag phase 3 rare disease drug
Mar 14, 2024 9:47am
